EGFR and glioblastoma: 65 patients with EGFR vIII-positive GBM were recruited, with a median overall survival (OS) of 21.8 months and a 3-year survival rate of 26%, which significantly prolonged the median survival of patients, proving the great efficacy of this vaccine [101].